PL1768677T3 - Kwasy nukleinowe do leczenia patologii związanych z HMGB-1 - Google Patents

Kwasy nukleinowe do leczenia patologii związanych z HMGB-1

Info

Publication number
PL1768677T3
PL1768677T3 PL05773148T PL05773148T PL1768677T3 PL 1768677 T3 PL1768677 T3 PL 1768677T3 PL 05773148 T PL05773148 T PL 05773148T PL 05773148 T PL05773148 T PL 05773148T PL 1768677 T3 PL1768677 T3 PL 1768677T3
Authority
PL
Poland
Prior art keywords
treatment
hmgb1
nucleic acids
related pathologies
nucleic acid
Prior art date
Application number
PL05773148T
Other languages
English (en)
Inventor
Domenico G Barone
Marco E Bianchi
Enrico M Bucci
Silvano Fumero
Margherita Valente
Roberto Sapio
Domenica Musumeci
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1768677(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Publication of PL1768677T3 publication Critical patent/PL1768677T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05773148T 2004-07-02 2005-07-04 Kwasy nukleinowe do leczenia patologii związanych z HMGB-1 PL1768677T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26
PCT/EP2005/007198 WO2006002971A2 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies
EP05773148A EP1768677B1 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies

Publications (1)

Publication Number Publication Date
PL1768677T3 true PL1768677T3 (pl) 2009-01-30

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05773148T PL1768677T3 (pl) 2004-07-02 2005-07-04 Kwasy nukleinowe do leczenia patologii związanych z HMGB-1

Country Status (14)

Country Link
US (1) US20080305073A1 (pl)
EP (1) EP1768677B1 (pl)
JP (1) JP2008504335A (pl)
AT (1) ATE399014T1 (pl)
AU (1) AU2005259381A1 (pl)
BR (1) BRPI0512944A (pl)
CA (1) CA2572519A1 (pl)
DE (1) DE602005007746D1 (pl)
DK (1) DK1768677T3 (pl)
ES (1) ES2306195T3 (pl)
IL (1) IL179828A0 (pl)
PL (1) PL1768677T3 (pl)
PT (1) PT1768677E (pl)
WO (1) WO2006002971A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
BRPI0707640A2 (pt) * 2006-02-09 2011-05-10 Transtech Pharma Inc proteÍnas de fusço do rage e mÉtodos de uso
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
KR20090087483A (ko) * 2006-11-17 2009-08-17 클리니컬 진 네트웍스 아베 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
WO2009140676A2 (en) * 2008-05-16 2009-11-19 Immune Disease Institute, Inc. Compositions and methods for inhibition of retroviruses
US8710021B2 (en) 2008-06-11 2014-04-29 Bionucleon S.R.L. Inhibition of HRP-3 using modified oligonucleotides
US8603766B2 (en) 2008-09-11 2013-12-10 Institut Pasteur Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
KR101431165B1 (ko) 2008-12-22 2014-08-18 크레아빌리스 에스.에이. 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
WO2012036215A1 (ja) 2010-09-17 2012-03-22 Taniguchi Tadatsugu Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018208369A1 (en) 2017-05-10 2018-11-15 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
WO2023250249A1 (en) * 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
CN115774004A (zh) * 2022-08-19 2023-03-10 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333350T2 (de) * 1992-10-14 2004-05-27 NeXstar Pharmaceuticals, Inc., Boulder Methode zur selektion von nukleinsäuren auf der basis ihrer struktur
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
WO2004046345A2 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents

Also Published As

Publication number Publication date
JP2008504335A (ja) 2008-02-14
EP1768677A2 (en) 2007-04-04
CA2572519A1 (en) 2006-01-12
IL179828A0 (en) 2008-03-20
AU2005259381A1 (en) 2006-01-12
BRPI0512944A (pt) 2008-04-15
EP1768677B1 (en) 2008-06-25
DK1768677T3 (da) 2008-10-20
ES2306195T3 (es) 2008-11-01
US20080305073A1 (en) 2008-12-11
PT1768677E (pt) 2008-10-06
WO2006002971A3 (en) 2006-04-20
WO2006002971A2 (en) 2006-01-12
ATE399014T1 (de) 2008-07-15
DE602005007746D1 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
PL1768677T3 (pl) Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
EP1670485A4 (en) TREATMENT OF ILLNESSES ASSOCIATED WITH THE EGR-1 AMPLIFIER ELEMENT
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE602005017027D1 (de) Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
WO2008101857A3 (en) Coryneform bacteria with formate-thf-synthetase and/or glycine cleavage activity
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
WO2008016906A3 (en) 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid
DE602005015297D1 (de) Verwendung von ozon zur verbesserung des knetvorgangs
WO2006132739A3 (en) Novel chemical compounds
MX341064B (es) Variantes de la familia il-1.
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602007001037D1 (de) Verfahren zur Herstellung von Acrylsäure
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
UA93658C2 (en) Cell surface glycoprotein
DE602007005288D1 (de) Verfahren zur Reinigung von Acrylsäure
WO2004089982A3 (en) April variants and methods thereof
WO2007049065A3 (en) Vwfa, collagen and kunitz domain containing protein
FR2882063B1 (fr) Methode de preparation de fragments synthetiques d'acides nucleiques bicatenaires